Provided by Tiger Trade Technology Pte. Ltd.

Akero Therapeutics

54.65
0.0000
Volume:- -
Turnover:836.20M
Market Cap:4.50B
PE:-14.61
High:54.65
Open:54.65
Low:54.65
Close:54.65
52wk High:58.40
52wk Low:21.34
Shares:82.32M
Float Shares:67.77M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7418
EPS(LYR):-3.7544
ROE:-34.53%
ROA:-22.63%
PB:4.70
PE(LYR):-14.56

Loading ...

BRIEF-Novo Nordisk Completes Acquisition Of Akero Therapeutics

Reuters
·
Dec 09, 2025

Novo Nordisk - Common Stock of Akero Will No Longer Be Listed or Traded on Nasdaq Global Select Market

THOMSON REUTERS
·
Dec 09, 2025

Novo Nordisk - Buys Akero for $4.7 Bln

THOMSON REUTERS
·
Dec 09, 2025

BRIEF-Germany's Cartel Office Says It Approved Acquisition Of Akero Therapeutics By Novo Nordisk

Reuters
·
Dec 04, 2025

Germany's Cartel Office Says It Approved Acquisition of Akero Therapeutics by Novo Nordisk

THOMSON REUTERS
·
Dec 04, 2025

BRIEF-Akero Therapeutics Stockholders Approve Acquisition By Novo Nordisk

Reuters
·
Dec 03, 2025

Akero Therapeutics Inc - Stockholders Approve Acquisition by Novo Nordisk - SEC Filing

THOMSON REUTERS
·
Dec 03, 2025

Akero Therapeutics Inc. Held Special Shareholder Meeting

Reuters
·
Dec 03, 2025

Hold Rating for Akero Therapeutics Amid SYNCHRONY MASH Progress and Novo Nordisk Acquisition

TIPRANKS
·
Nov 14, 2025

Sector Update: Health Care Stocks Edge Higher Late Afternoon

MT Newswires Live
·
Nov 14, 2025

Market Chatter: Novo Nordisk Raises $4.7 Billion in Bond Sale to Fund Akero Acquisition

MT Newswires Live
·
Nov 14, 2025

Novo Nordisk Bond Sale to Fund Akero Acquisition Raises $4.7 Billion, Bloomberg Reports

MT Newswires Live
·
Nov 14, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 12, 2025

BRIEF-Akero Therapeutics Presents New Phase 2b Trial Data On Efruxifermin At AASLD Liver Meeting 2025

Reuters
·
Nov 07, 2025

Akero Therapeutics announces new findings from SYMMETRY, HARMONY trials

TIPRANKS
·
Nov 07, 2025

Akero Therapeutics Reports Efruxifermin Shows Antifibrotic Activity in 96-Week MASH Trials

Reuters
·
Nov 07, 2025

Akero Therapeutics Presents New Analyses From Phase 2B Symmetry and Harmony Trials of Efruxifermin at 76TH Annual Aasld the Liver Meeting® 2025

THOMSON REUTERS
·
Nov 07, 2025

Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025

GlobeNewswire
·
Nov 07, 2025

Biotech M&A Deals Are Trickier Than They Look. Watch the Milestone Payments. -- Barrons.com

Dow Jones
·
Nov 07, 2025

Akero Therapeutics Inc. Announces Date for Upcoming Special Stockholder Meeting

Reuters
·
Oct 25, 2025